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Abstract Since 1948, epidemiology studies played an impor-
tant role in understanding cardiovascular disease and afforded
an opportunity to learn about newer diagnostic tests. In 2000,
the MESA Study incorporated several advanced cardiovascu-
lar imaging modalities including cardiac magnetic resonance
imaging (MRI) and coronary artery calcium scans. The decade
of follow-up enabled prognosis studies, an important step be-
yond association studies. In brief, left ventricular hypertrophy
by cardiac MRI predicted incident heart failure and stroke. In
the MESA Study, coronary artery calcium was a better predic-
tor of coronary artery disease end points than the non-contrast-
enhanced MRI scan. In the ICELAND MI substudy of the
AGES-Reykjavik Study, a contrast-enhanced MRI scan de-
tected many more unrecognized myocardial infarctions
(MIs) (UMIs) than detected by electrocardiography and doc-
umented these UMI had adverse prognostic significance.
Thus, cardiac MRI has been successfully incorporated into
large population studies and shown added value over conven-
tional measurements of cardiovascular disease.
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Introduction
Prospective cohort studies focused on cardiovascular disease
have had major impact on the understanding of cardiovascular
disease. The Framingham Study was established in 1948 to
study the general causes of atherosclerotic and hypertensive
cardiovascular disease [1]. The study focused on a randomly
selected population where arteriosclerotic and hypertensive
cardiovascular diseases were known to develop. The subjects
were characterized with clinical examination at the onset of
the study when they were free of known disease and followed
until a sizable number of the subjects acquired diseases. A
major accomplishment involved identification of the major
risk factors associated with development in coronary artery
disease and codified in the Framingham risk score [2]. The
concept of cardiovascular risk factors became integrated into
the practice of medicine and remains an important approach to
patients to the present day. It is intriguing that the first publi-
cation describing the Framingham Study specifically also in-
dicated that this was an opportunity to use and learn about
some of the most recent diagnostic tests [1]. The concept of
using new technologies in cardiovascular epidemiology has
continued in population studies in the current era. This per-
spective paper will highlight some uses of cardiovascular
magnetic resonance (CMR) in a few of the recent population
studies focused on cardiovascular disease.
Different Levels of Clinical Research Related to Study
Design
Epidemiology studies are one of many clinically relevant re-
search methods that can help us understand the natural history
of disease and gain new insights about diagnostic procedures.
Epidemiology studies may provide insights to human disease
at many different levels that parallel other types of clinical
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studies (Fig. 1). Associations between observations and
disease-related characteristics represent the most common lev-
el of information in epidemiology studies. When enough sub-
jects are followed to development of clinical outcomes, one
can discuss conclusions regarding prognosis of subjects, a
method used to define landmark findings such as the
Framingham Risk Score. However, there is an implicit indi-
rectness between causation and either associations or progno-
sis. On the other hand, prognosis studies generally are a stron-
ger level of evidence between a characteristic and the eventual
disease outcome. One of the purposes of this review will be to
discuss association studies and outcome studies from within
the same cohort.
Clinical registries represent collective experiences in many
patients in an attempt to derive generalizable information. The
sample size of registries can be quite large, often substantially
larger than feasible in epidemiology or randomized controlled
clinical trials. The promise of registries is that these accumulat-
ed experiences in large numbers of actual patients may reflect
the real-world experience better than clinical trials which may
restrict inclusion criteria to a degree that a small fraction of
patients are eligible. The EuroCMR registry reported initial
experience in about 11,000 subjects in 2009 [3] but was able
to increase the sample size to ~27,000 patients by 2013 [4]. The
EuroCMR registry was able to summarize the overall low
frequency of adverse events reported in 17,767 doses of
gadolinium-based contrast agents, a result that would be diffi-
cult to achieve in single center studies. Focused registry studies
can address clinically relevant questions. For example, the
EuroCMR registry had sufficient power to show the prognostic
significance of any late gadolinium enhancement in a
preliminary analysis of 249 patients with hypertrophic cardio-
myopathy [4]. Information from registries may come at the cost
of less precise inclusion criteria and the unknown vagaries of
biases introduced by lack of randomization and other controls
typically found in formal clinical trials. However, it is clear that
all levels of clinical research can contribute to our understand-
ing of cardiovascular disease and can also answer questions
about technology like CMR. This review will not further ad-
dress registries.
Some Epidemiology Studies Which Used CMR
in Prognosis Level Studies
The MESA Study (Multi-Ethnic Study of Atherosclerosis)
was designed starting in 2000 and aimed to investigate the
prevalence, correlates, and progression of subclinical cardio-
vascular disease (CVD) in a population-based sample of 6500
men and women aged 45–84 years [5]. In the spirit of incor-
porating new technologies, MESA incorporated coronary cal-
cium scans, cardiac magnetic resonance imaging, flow-
mediated brachial artery endothelial vasodilation, carotid ul-
trasound of intimal-medial wall thickness, and ankle and bra-
chial blood pressure indices. Due to low event rates, the study
has been extended beyond the initial planned endpoint of
2008. This tincture of time has allowed relating many mea-
surements to cardiovascular disease end points including
many related to CMR.
The Dallas Heart Study also incorporated CMR as a base-
line measurement of the cohort. [6] Overall, the Dallas Heart
study characterized 6101 subjects from 2000 to 2002 and was
extended with a longitudinal component in 2007. Cooperation
Fig. 1 Epidemiology studies can
have substudies that parallel and
complement other levels of
clinical trials. These types of
human studies can be done at a
wide range of complexity, design,
control, and regulation.
Exploratory studies within an
epidemiology study represent the
equivalent of pilot studies.
Examples of association studies
and prognosis studies are
discussed extensively in this
article
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between the Dallas Heart Study investigators and MESA in-
vestigators aimed to design acquisition protocols that were
comparable, a foresight that could lead to future collaborative
efforts.
The ICELAND-MI (Imaging Cardiac Evaluation to Locate
Areas of Necrosis and Detect MI) was a substudy of the
AGES-Reykjavik Study (Age, Gene/Environment
Susceptibility–Reykjavik Study). The parent cohort study
was initiated in 2002 and was designed to address risk factors
for diseases prevalent in older subjects including cardiovascu-
lar disease, cognitive dysfunction, musculoskeletal diseases,
and body composition and metabolism [7]. As with MESA, a
wide range of biomarkers, imaging, and other physiologic
indicators were obtained in the approximately 5700 partici-
pants. From a cardiovascular MRI perspective, the use of gad-
olinium to detect unrecognized myocardial infarction (MI)
was relatively unique use of new technology for a population
study [8•]. The Prospective Investigation of the Vasculature in
Uppsala Seniors (PIVUS) study also used gadolinium-
enhanced cardiac MRI in a study of 70 year old males in
Uppsala, Sweden [9].
These studies form the basis for discussion in the following
sections but must be recognized as a limited window in the
range of epidemiology studies that have also used CMR.
Associations and Prognosis Related to Left Ventricular
Hypertrophy and Left Ventricular Remodeling
CMR is recognized as a reference standard method for mea-
suring left ventricular volumes, left ventricular ejection frac-
tion, left ventricular myocardial mass, and left ventricular hy-
pertrophy (LVH) [10–12]. These studies generally found that
MRI is more reproducible when measuring myocardial mass
and ejection fraction than echocardiography. The MESA in-
vestigators also found that ECG criteria are relatively insensi-
tive (10–26 %) to LV hypertrophy relative to MRI but
quite specific (88–99 %) [13]. MRI-determined LVH
and LV remodeling have been associated with a variety
of cardiovascular phenotypes and, more recently, cardio-
vascular outcomes.
In a study that represents the intersection of genetics, epi-
demiology, imaging, and pathophysiology, the Dallas Heart
Study investigators described the association between genetic
susceptibility to LVH and the observedMRI phenotypic LVH.
These findings were validated in theMESA cohort [14]. Corin
is a type II transmembrane serine protease that converts pro-
A-type naturetic peptide and pro-B-type naturetic peptide into
biologically active compounds [15, 16]. In general terms, one
action of the natriuretic peptide system within the heart is to
counter the development of cardiac hypertrophy. Dries et al.
demonstrated that the corin gene minor allele defined by two
missense mutations (single-nucleotide polymorphisms (T555I
and Q568)) is common in African American subjects and
associated with hypertension [17]. They hypothesized that
the minor corin I555(P568) allele would be associated with
an enhanced hypertrophic response to pressure overload in the
Dallas Heart Study. The minor corin I555(P568) allelic prev-
alence was ~6% in African Americans and was uncommon in
people with European ancestry. The subjects with the minor
corin variant had a greater LV mass than the subjects with the
wild-type allele at higher blood pressures.
With respect to the minor corin I555(P568) allele, the find-
ings in the MESA cohort replicated those observed in the
Dallas Heart Study and strengthened the conclusion that the
LVHwas not simply a result of hypertension. The relationship
between LV mass and blood pressure was modulated in a
similar pattern as observed in the Dallas Heart Study. More
importantly, in the MESA study, the subjects with the minor
corin allele had similar blood pressure to those without the
variant which further supports the conclusion that these effects
most likely represent anti-hypertrophic effects of the natriuret-
ic peptide system rather than simply direct effects of blood
pressure. One can argue that this level of genotypic and phe-
notypic analysis might not have worked unless the key genetic
and phenotypic measurements were reproducible and precise.
The association between LV mass and ankle brachial index
in the MESA study highlights ways that epidemiology studies
and imaging can assess pathophysiological correlates in
humans. The ankle brachial index is the ratio of blood pressure
at the ankle divided by blood pressure at the brachial artery.
An ankle brachial index <0.90 generally reflects atheroscle-
rotic disease in the peripheral arteries leading to the legs. An
ankle brachial index >1.40 is thought to represent a stiff
arterial wall that is not typical of atherosclerosis and is more
likely explained by medial arterial calcification. Ankle brachi-
al indices between these extremes are considered normal.
MESA investigators confirmed a previous observation that a
low or a high ankle brachial index was associated with in-
creased LV mass relative to the subjects with a normal ankle
brachial index (p<0.001 for both comparisons) [18]. More
interestingly, they hypothesized that low ankle brachial index
should relate to subclinical atherosclerosis while abnormally
high ankle brachial index should not. In multivariable models
that included coronary risk factors, coronary artery calcium,
and carotid intimal medial thickness, the relationship between
LV mass and low ankle brachial index was eliminated as ex-
pected for an underlying pathophysiology related to athero-
sclerosis. The high ankle brachial index group still showed
increased LV mass relative to the participants with normal
ankle brachial index consistent with their hypothesis that in-
compressible peripheral vessels are a different pathophysiol-
ogy—medial arterial calcification. This study illustrates again
the power of subclinical imaging measurements of atheroscle-
rosis and the ability of sophisticated analyses of associations
to find relationships between complex disease and the conse-
quences in humans.
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In a study that raises questions about which came first, the
hypertension or the LVH, the MESA investigators looked at
the associations between baseline LV mass and LV geometry
in 2567 subjects that did or did not develop hypertension over
the subsequent median follow-up of 4.8 years [19]. Contrary
to textbook teaching, baseline LV mass alterations preceded
development of hypertension. While an association study of
this nature can be criticized frommany directions, it also chal-
lenges many basic teachings. Since this finding has also been
seen in three prior studies [20–22], one should start to consider
what pathophysiological mechanisms might explain the find-
ings. Perhaps genetic factors lead to parallel increases in LV
mass and the peripheral factors that lead to hypertension.
Neurohormonal mechanisms could have affected arterial stiff-
ness and LV hypertrophy prior to clinically recognized hyper-
tension. Perhaps, LV hypertrophy itself leads to changes in
stroke volume or other hemodynamic changes that ultimately
contribute to recognized hypertension. Maybe the LV hyper-
trophy is explained by pre-hypertension or unrecognized hy-
pertension that resolved prior to baseline characterization.
Some lines of research are difficult to address without as-
sociation studies. For example, the consequences of air pollu-
tion on cardiovascular disease or abnormalities may be impos-
sible to study in controlled human experiments. On the other
hand, air pollution is associated with increased incidence of
heart failure and mortality. TheMESA investigators examined
the association between air pollution and LV mass in a study
aimed at trying to tease out potential mechanism for the rela-
tionship between air pollution and heart failure [23]. Relative
exposure to particulate air pollution was estimated by dividing
subjects into those that lived within 50 m of a major highway
versus those that lived >150 m from major highways using
U.S. Environmental Protection Agency (EPA) Air Quality
System monitor data. Exposure was interpolated to the home
location of each participant. In brief, they found that LV mass
index increased by 1.4 g/m2 for participants living within 50m
of a major roadway when compared with those that lived
>150 m from a major roadway. In a related study of 3896
MESA participants that had MRI measurements of the right
ventricle, higher estimated exposure to traffic-related air pol-
lution in the form of nitrogen dioxide was associated with
greater right ventricular mass and volumes [24]. This associ-
ation was significant in multivariable models that adjusted for
left ventricular measurements, traffic noise estimates, inflam-
matory markers, and lung disease. Again, the difficulties in
fundamental measurements for studies like this are substantial.
That any relationships were found is rather remarkable but
will need independent confirmation.
Renal failure is associated with diastolic dysfunction, heart
failure, and cardiovascular mortality. Cystatin C is a good
marker of renal function [25, 26]. In a study of 4970 MESA
participants, cystatin C was inversely related to LV end-
diastolic and LV end-systolic volumes but not related to LV
mass in fully adjusted models accounting for blood pressure
and antihypertensive treatment, among other factors. Cystatin
C was also directly related to LV concentric remodeling, a
parameter defined by an increase in relative wall thickness
>0.42 without an increase in left ventricular mass [27]. In
contrast, the Dallas Heart Study found that cystatin C was
related to LV mass but not to LV end-diastolic volume [28].
While differences in the populations and the duration of renal
dysfunction may explain differences between studies, this ex-
ample illustrates the limitations of association studies even in
the best of circumstances. On the other hand, some of the
underlying pathophysiology and confounding factors may
not be completely understood. Thus, this remains an area for
future research.
Considering the overall strength of LV hypertrophy in the
association studies, it should not be surprising that LV hyper-
trophy by MRI has also been a good prognosticator in subse-
quent studies. The MESA investigators described the relation-
ship between left ventricular mass and incident cardiovascular
events in one of the first epidemiology prognosis studies using
CMR [29]. Earlier that year, they had described the racial
differences related to incident heart failure which showed
African Americans at highest risk, Caucasians at intermediate
risk, and Chinese participants at lowest risk [30]. Heart failure
was associated with hypertension, diabetes, and LV hypertro-
phy. Incident MI had preceded heart failure in about 50 % of
subjects.
More recently, the MESA investigators described the prog-
nostic significance of left ventricular dilatation by CMR for
incident heart failure [31]. Participants with dilated LV and
normal ejection fraction had an increased risk of heart failure
(hazard ratio 2.22) but participants with dilated LV and de-
creased ejection fraction had even worse prognosis (hazard
ratio 7.35) relative to those with normal size LV and normal
ejection fraction.
Although LV mass tended to decrease with age, the LV
mass-to-volume ratio increased due to a reduction in LV
end-diastolic volume. Age was also associated with regional
systolic and diastolic myocardial dysfunction despite an en-
hanced ejection fraction. Increased LV mass-to-volume ratio
conferred a significant risk for total cardiovascular events rep-
resented by incident MI, angina, heart failure, strokes, and
coronary artery disease related deaths [32].
In another study that points to the difference between asso-
ciations and prognosis studies, the MESA investigators looked
at the associations between obesity and heart failure. They
found that incident heart failure was better explained by LV
hypertrophy and LVejection fraction than by measures of obe-
sity. With 168 subjects that developed heart failure, body mass
index and waist circumference were associated with incident
heart failure. However, the associations with obesity were better
explained by conditions frequently encountered in the obese
including hypertension, hyperglycemia, hypercholesterolemia,
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left ventricular hypertrophy, kidney disease, and inflammation
[33].
Left ventricular hypertrophy and remodeling are not the
only CMR parameters that predict heart failure. In a case–
control study nested within MESA, left atrial function was a
significant predictor of heart failure in multivariable analysis
that included NT-pro-BNP, LV mass, and clinical risk factors
[34]. In another study, left ventricular hypertrophy on ECG
added significantly in prediction of atrial fibrillation in a mod-
el that included LV hypertrophy by MRI. This is an
indication that similar parameters with different thresh-
olds may capture different aspects of the underlying
pathology. MRI left ventricular hypertrophy may benefit
from sensitivity while ECG left ventricular hypertrophy
may retain prognostic significance due to high specific-
ity [35•]. Right ventricular enlargement had prognostic
significance for heart failure in models that included left
ventricular mass [36]. The effect of increased RV mass
was more prominent in participants with lower left ven-
tricular mass. The association of right ventricular enlargement
did not survive multivariable analysis that included LV vol-
umes. Right ventricular ejection fraction was not associated
with incident heart failure.
Associations and Prognosis Related to Regional Wall
Motion
Left ventricular mass and left ventricular hypertrophy have
clear pathophysiological relationships to hypertension, vascu-
lar compliance, and pressure overload. Thus, there are rela-
tively direct relationships between left ventricular mass or left
ventricular hypertrophy and heart failure. The hypertension
association plausibly links to risk of stroke but the association
is more indirect. Left ventricular mass, as a biomarker for
coronary artery disease, is clearly less directly linked to the
pathophysiology of coronary artery disease and myocardial
infarction. Beyond left ventricular mass, MESA has studied
a few biomarkers by cardiacMRI that might relate more close-
ly to coronary artery disease.
Several papers have reported results from quantifying
regional myocardial systolic function with strain analy-
sis of tagged MRI studies in the MESA cohort. Since
coronary artery disease is the leading cause of regional
wall motion abnormalities, it was postulated that quan-
tification of regional myocardial function might be as-
sociated with coronary artery disease [37]. While subtle, there
was a relationship between the coronary specific calcium
score and the regional myocardial strain that was statistically
significant (Fig. 2).
The MESA investigators also quantified regional myocar-
dial systolic function by measuring wall thickening on cine
MRI and used these data in a prognosis study [38]. They
found a surprisingly high prevalence of regional myocardial
dysfunction in the asymptomatic MESA participants at base-
line (25.6 %). However, with 4.6 years average follow-up,
incident heart failure occurred about 2.6 times as often in
participants with baseline regional wall thickening abnormal-
ities than those without. Regional myocardial dysfunction also
predicted hard coronary events including stroke and all ath-
erosclerotic cardiovascular events.
Regional left ventricular diastolic relaxation abnormalities
can be quantified by cardiac MRI tagging studies (Fig. 3) and
could relate to heart failure. In a sub-study of 218 MESA
participants, there was a direct relationship between regional
left ventricular diastolic dysfunction and left ventricular hy-
pertrophy [39]. Again, the difference between diastolic strain
as segmented by quartiles of left ventricular mass index were
relatively subtle but statistically consistent with a stepwise
association. This association finding is intriguing as a preclin-
ical manifestation of myocardial abnormalities. The finding is
even more interesting considering that the MESA participants
were asymptomatic at the time of study and had no clinically
Fig. 2 Higher regional coronary calcium score was associated with
worse regional systolic function in participants of the MESA Study.
(Reproduced with permission from: Edvardsen T, Detrano R, Rosen
BD, Carr JJ, Liu K, Lai S, Shea S, Pan L, Bluemke DA, Lima JA.
Coronary artery atherosclerosis is related to reduced regional left
ventricular function in individuals without history of clinical
cardiovascular disease: the Multiethnic Study of Atherosclerosis.
Arterioscler Thromb Vasc Biol. 2006;26 (1):206–211) [37]
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recognized cardiovascular disease. With 8 years of longitudi-
nal follow-up, the MESA study recently showed that cardiac
MRI evidence of abnormal diastolic function predicted inci-
dent heart failure and atrial fibrillation [40].
In a study that borders between association and prognosis,
regional myocardial systolic function as measured by cardiac
MRI tagging was used as a surrogate end point [41]. In 785
MESA participants that had cardiacMRI tagging studies at base-
line and at 5-year follow-up, elevated high sensitivity c-reactive
protein (hs-CRP) at baseline was associated with interval de-
creases in regional myocardial function. These changes were
significant in multivariable analyses that included risk factors
for coronary disease, renal dysfunction, left ventricular mass,
coronary calcium score, and interim clinical coronary events.
Associations with Stress Perfusion CMR
AMESA substudy used gadolinium enhanced, stress perfusion
CMR in 222 subjects. This study used fully quantitative analy-
sis of rest myocardial blood flow, stress myocardial blood flow,
and perfusion reserve, a substantial technical tour de force.
After adjusting for age, gender, and race, the MESA investiga-
tors found that reduced myocardial perfusion reserve was inde-
pendently associated with hypertension, higher diastolic blood
pressure, and higher total and low-density lipoprotein choles-
terol, but was not associated with cigarette smoking, obesity,
physical activity, or diabetes [42]. Absolute stress myocardial
blood flow and myocardial perfusion reserve were inversely
correlated with estimated 10-year CHD risk based on
Framingham equations in that study.
In further analysis, absolute myocardial stress perfusion and
myocardial perfusion reserve both decreased monotonically ver-
sus coronary artery calcium score categorized as 0, 1–99, 100–
399, and ≥400 [43]. Rest myocardial blood flow did not vary as a
function of calcium score as one would expect in
asymptomatic subjects. It is important to recognize that
the subjects in this study did not have clinically recognized
coronary artery disease and were asymptomatic. Thus, the
stress perfusion findings either represent a subclinical abnor-
mality in coronary artery reactivity to vasodilators or subclin-
ical coronary artery stenoses.
A subset of subjects in MESA had both stress perfusion
and rest myocardial tagging CMR to assess regional function.
In these 77 subjects, there was an association between lower
perfusion reserve and abnormal regional function as measured
by strain analysis, but the findings were relatively weak and
not completely consistent across different coronary artery per-
fusion territories [44]. Again, the fact that the study partici-
pants were asymptomatic from a coronary disease perspective
makes it unlikely to find associations for this type of patho-
physiological condition unless the subclinical disease has
progressed to a point of having a physiologically significant
coronary artery stenosis.
Associations and Prognosis Related to Carotid CMR
MRI of the carotid arterial wall can assess arterial wall thick-
ness, a parameter related to but not identical to intimal medial
thickness. MRI can also assess characteristics of atheroma in
the carotid arteries (Fig. 4). The quality of these vascular find-
ings is enhanced by the proximity of the carotid arteries to the
skin. An ancillary study of 577 subjects from MESA found
associations with carotid plaque. In a study of subjects select-
ed based on carotid intimal medial thickness by ultrasound in
the upper 15th percentile, atheroma with a lipid core by MRI
were associated with the middle and upper tertile of total cho-
lesterol. That association held in multivariable models that
Fig. 3 Regional systolic and diastolic function can be quantified from
tagged cardiac MR images. The figures show left ventricular strain rate
and strain across the cardiac cycle. The BE-wave^ reflects the strain rate
associated with early diastolic filling. The BA-wave^ reflects the strain rate
associatedwith atrial contraction. Strain represents the percent change in the
dimension of the myocardial (roughly percent thickening of the wall).
Strain rate is the rate of change if strain. (Reproduced with permission
from: Edvardsen T, Detrano R, Rosen BD, Carr JJ, Liu K, Lai S, Shea S,
Pan L, Bluemke DA, Lima JA. Coronary artery atherosclerosis is related to
reduced regional left ventricular function in individuals without history of
clinical cardiovascular disease: the Multiethnic Study of Atherosclerosis.
Arterioscler Thromb Vasc Biol. 2006;26(1):206–211) [37]
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included clinical risk factors, carotid intimal medial thickness
by ultrasound, and hs-CRP [45].
In a subsequent study of 946 MESA participants that had
carotid MRI, at total of 59 (6 %) had cardiovascular events in
an average follow-up of 5.5 years. The MESA investigators de-
fined an MRI index of carotid remodeling as an increased wall
area to lumen cross-sectional area. They found that increased
vessel wall remodeling and presence of a plaque with a lipid core
predicted cardiovascular events [46].
In what would be best characterized as an Bexploratory^
study, the MESA investigators used MRI to examine the cor-
onary arterial wall using black blood techniques in 179 study
participants [47]. In brief, coronary MR angiography did not
detect any definite coronary artery stenosis. They did find
evidence of coronary arterial wall remodeling. A coronary
wall thickness >2 mm was associated with an Agatston score
>0. This is an example of a nested study using technology not
routinely used in clinical practice.
Associations and Prognosis Related to CMR
of Recognized and Unrecognized MI
The ICELAND-MI substudy of AGES-Reykjavik was de-
signed to determine the prevalence and prognosis of recognized
and unrecognized myocardial infarction in a community-
dwelling cohort of Icelandic adults over the age of 67 [8•].
The study included 936 participants from AGES-Reykjavik.
They were recruited in two phases. Phase 1 was a random
cross-section of the main cohort. Phase 2 was a targeted recruit-
ment of participants with diabetes. Based largely around late
gadolinium-enhanced MRI of myocardial infarction (Fig. 5),
Iceland MI had several important findings. The prevalence of
Fig. 4 Examples of MRI characterization of atherosclerotic plaque in the
carotid arteries of a participant in the MESA study. Black blood images
taken through thickest part of the plaque (middle line, Fig. 1). Flow
suppression was achieved using a double inversion recovery turbo spin
echo sequence with cardiac gating. Chemical suppression of fat signal
was applied. T1-weighted pre- and post-contrast (a and b, respectively)
and T2-weighted (c) images were acquired (acquired resolution, 2 mm,
0.54 mm, 0.54 mm). The conspicuity of the lipid core (schematic, d) was
improved after administration of the gadolinium-based contrast agent (a,
b). (Reproduced with permission from: Wasserman BA, Sharrett AR, Lai
S, Gomes AS, CushmanM, Folsom AR, Bild DE, Kronmal RA, Sinha S,
Bluemke DA. Risk Factor Associations with the Presence of a Lipid Core
in Carotid Plaque of Asymptomatic Individuals Using High-Resolution
MRI. The Multi-Ethnic Study of Atherosclerosis (MESA). Stroke.
2008;39(2):329–335) [45]
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recognized MI was 9.7 % overall while the prevalence of un-
recognized MI was 17 %. The unrecognized MIs were
associated with cardiovascular disease risk factors, coronary
calcium, coronary revascularization, and peripheral vascular
Fig. 5 Examples of recognized and unrecognized myocardial infarctions
in the ICELAND-MI Study. All images are short-axis view, cardiac
magnetic resonance (CMR) with late gadolinium enhancement (LGE)
on the left and end-diastolic cine frames on the right. a Recognized
myocardial infarction (MI) involving the typical left anterior descending
artery distribution (arrowhead). On LGE images, an MI is brighter than
remote or normal myocardium, which appears dark. b Participant with no
evidence of MI. The myocardium is uniformly dark (Bnulled^) on the
LGE image. c Unrecognized MI in the basal inferolateral wall
(arrowhead). d Two unrecognized MIs in different coronary territories
in the same participant. (Reproduced with permission from: Schelbert
EB, Cao JJ, Sigurdsson S, Aspelund T, Kellman P, Aletras AH, Dyke
CK, Thorgeirsson G, Eiriksdottir G, Launer LJ, Gudnason V, Harris TB,
Arai AE. Prevalence and prognosis of unrecognized myocardial
infarction determined by cardiac magnetic resonance in older adults.
JAMA. 2012 Sep 5;308(9):890–6) [8•]
Fig. 6 For participants with unrecognized myocardial infarctions (MIs),
all-cause mortality was significantly worse than for subjects with no MI
and comparable to those with recognized MI. (Reproduced with
permission from: Schelbert EB, Cao JJ, Sigurdsson S, Aspelund T,
Kellman P, Aletras AH, Dyke CK, Thorgeirsson G, Eiriksdottir G,
Launer LJ, Gudnason V, Harris TB, Arai AE. Prevalence and prognosis
of unrecognized myocardial infarction determined by cardiac magnetic
resonance in older adults. JAMA. 2012 Sep 5;308(9):890–6) [8•]
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disease—a set of associations that were reassuring that the im-
aging findings were consistent with subclinical coronary dis-
ease. The prognosis of unrecognized MI was significantly
worse than in subjects without any type of MI and was compa-
rable to the prognosis of recognized MI (Fig. 6). Finally, the
subjects with unrecognized MI were less likely to be treated
with cardiovascular medications than those with recognizedMI
suggesting potential for better risk modification.
The high prevalence of unrecognizedMI was also found in
the Prospective Investigation of the Vasculature in Uppsala
Seniors (PIVUS) study in Uppsala, Sweden [9] The PIVUS
study found that unrecognized MI was associated with stroke,
again emphasizing the clinical relevance of myocardial scar
[48]. These population studies reflect the clinical impressions
of how powerful these methods are for characterizing myocar-
dial infarction. They also indicate that cardiac MRI can assess
parameters predictive of coronary artery disease.
Relative Predict Power of Biomarkers for Cardiovascular
Disease Outcomes
There is a natural tendency in studies to focus a hypothesis or
specific aim on a particular parameter of interest. One always
wonders how well parameters that are predictive in one study
would be if the authors had considered other biomarkers.
One study from MESA has taken the challenge to examine
relative predictive power of three imaging biomarkers and tradi-
tional risk factors for predicting coronary heart disease outcomes,
heart failure events, and strokes [49•]. They defined coronary
artery disease outcomes broadly and used a formal adjudication
process including the following determinations: definite or prob-
able myocardial infarction, resuscitated cardiac arrest, definite
angina, probable angina, and definite or probable CHD death.
Stroke was defined as fatal or nonfatal stroke but excluded tran-
sient ischemic attacks. Heart failure included definite or probable
Table 1 Summary of the relative prognostic power of three imaging biomarkers for three different cardiovascular outcomes in the MESA study
Measure <50th
percentile
3rd quartile 4th quartile
Overall (n=4965) Men (n=2365) Women (n=2600) Overall (n=4965) Men (n=2365) Women (n=2600)
CHD (n=187)
CAC Score Ref 3.2 (1.9–5.4)* 3.4 (1.7–6.9)* 2.6 (1.1–6.1)† 6.6 (3.9–10.9)* 7.6 (3.9–14.8)* 5.2 (2.2–12.1)*
Carotid IMT Ref 1.5 (0.9–2.4) 1.3 (0.8–2.1) 2.7 (1.1–6.6)† 2.0 (1.3–3.1)* 1.7 (1.0–2.7)† 3.7 (1.5–9.0)‡
LV mass Ref 0.8 (0.5–1.2) 0.7 (0.5–1.2) 1.1 (0.5–2.2) 1.2 (0.9–1.7) 1.2 (0.8–1.8) 1.4 (0.7–2.8)
LV mass/volume Ref 0.8 (0.6–1.3) 1.1 (0.6–1.8) 0.5 (0.2–1.1) 1.5 (1.0–2.1)† 1.8 (1.1–2.8)† 1.1 (0.6–2.1)
Stroke (n=65)
CAC score Ref 0.9 (0.4–1.7) 1.1 (0.3–4.4) 0.8 (0.4–1.9) 1.1 (0.5–2.1) 2.1 (0.6–7.0) 0.7 (0.3–1.8)
Carotid IMT Ref 0.6 (0.3–1.1) 0.8 (0.3–2.4) 0.4 (0.2–1.2) 0.7 (0.4–1.4) 0.7 (0.3–2.0) 0.8 (0.4–1.8)
LV mass Ref 2.5 (1.3–4.8)‡ 2.9 (1.1–8.3)† 2.0 (0.8–4.9) 2.3 (1.2–4.4)† 1.8 (0.6–5.4) 2.6 (1.1–6.1)†
LV mass/volume Ref 2.2 (1.0–4.4)† 1.8 (0.5–6.6) 2.1 (0.8–5.0) 2.9 (1.4–5.7)‡ 2.3 (0.7–7.3) 3.1 (1.3–7.4)‡
Heart failure
CAC score Ref 0.8 (0.4–1.6) 0.6 (0.3–1.5) 1.1 (0.4–3.2) 1.6 (0.9–2.8) 1.1 (0.5–2.4) 2.7 (1.1–6.9)†
Carotid IMT Ref 0.9 (0.5–1.6) 0.7 (0.3–1.5) 1.1 (0.4–3.2) 0.9 (0.6–1.7) 0.8 (0.4–1.5) 1.4 (0.5–3.8)
LV mass Ref 1.5 (0.8–2.8) 1.1 (0.4–2.6) 2.3 (0.9–6.3) 3.9 (2.3–6.7)* 4.9 (2.6–9.5)* 3.0 (1.2–7.7)†
LV mass/volume Ref 0.6 (0.3–1.1) 0.4 (0.2–0.9)† 0.9 (0.4–2.5) 0.9 (0.5–1.5) 0.7 (0.4–1.2) 1.4 (0.6–3.3)
All CVD
CAC score Ref 1.5 (1.0–2.1)† 1.6 (0.9–2.7) 1.2 (0.7–2.2) 2.9 (2.0–4.0)* 3.6 (2.3–5.8)* 2.2 (1.3–3.7)‡
Carotid IMT Ref 1.2 (0.8–1.6) 1.2 (0.8–1.8) 1.1 (0.6–1.9) 1.3 (0.9–1.8) 1.3 (0.9–1.9) 1.4 (0.8–2.4)
LV mass Ref 1.0 (0.8–1.4) 0.9 (0.6–1.4) 1.4 (0.8–2.2) 1.7 (1.3–2.2)* 1.8 (1.2–2.5)* 1.6 (0.9–2.6)
LV mass/volume Ref 0.9 (0.7–1.3) 0.9 (0.6–1.3) 0.9 (0.6–1.6) 1.4 (1.0–1.8)† 1.4 (0.9–2.0) 1.2 (0.7–1.9)
The hazard ratios and 95% confidence intervals are for incident cardiovascular disease as predicted by imagingmeasures of subclinical disease treated as
categorical variables. Coronary artery calcium was a powerful predictor of incident coronary and all cause cardiovascular events. MRI left ventricular
mass or LV mass/volume ratio were strong predictors of incident stroke and heart failure. CAC score refers to the natural logarithm of (CAC+1) values.
Carotid IMT refers to a composite z score for overall maximal IMT. LVmass was adjusted for body size when implied as a separate imaging measure but
not in LV mass/volume ratio. HR expresses hazard in relation to the first two quartiles as reference. Boldface indicates imaging measures showing the
highest HR for each event type. The results presented are based on the model adjusted for both traditional risk factors as well as imaging-derived
measures. (Reproduced with permission from: Jain A, McClelland RL, Polak JF, Shea S, Burke GL, Bild DE, Watson KE, Budoff MJ, Liu K, Post WS,
Folsom AR, Lima JA, Bluemke DA. Cardiovascular Imaging for Assessing Cardiovascular Risk in Asymptomatic Men Versus Women: The Multi-
Ethnic Study of Atherosclerosis (MESA). Circ Cardiovasc Imaging. 2011;4(1):8–15) [49•]
*p≤0.001; † p<0.05; ‡ p≤0.01
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events. The study included 4965 subjects from MESA that had
coronary artery calcium score quantified by CT, left ventricular
mass and volumes imaged by MRI, and carotid intimal medial
thickness measured by ultrasound.
With 187 coronary heart disease events, 91 heart failure
events, and 65 strokes, they found that coronary calcium
was the strongest predictor of coronary heart disease and car-
diovascular disease end points (Table 1). LV mass by cardiac
MRI was the strongest predictor of heart failure events and
incident stroke. In models based on traditional risk factors to
predict coronary heart disease end points, the addition of cor-
onary artery calcium improved the area under the curve as did
adding the combination of all three imaging biomarkers
(Table 1). The number of events and the lack of predefined
categories of risk for stroke and heart failure complicated net
reclassification index for these outcomes. With respect to pre-
diction of coronary heart disease as an end point, it should not
be surprising that coronary artery calcium is a good biomarker
as it closely correlates with coronary atherosclerosis and it
localizes in the arteries supplying the heart.
The relative prognostic value of NT-pro-BNP and CMR
measurements has also been studied in the MESA cohort
[50]. NT-pro-BNP predicted incident heart failure indepen-
dent of clinical risk factors, renal function, LV mass index,
and incident MI. Traditional risk factors had an area under
the curve of 0.81. Addition of LV mass index increased the
area under the curve to 0.85 while addition of NT-pro-BNP
further increased area under the curve to 0.89. Those statistics
compete very favorably with diagnostic accuracy tests.
Conclusions
While this has not been a 100 % comprehensive review of all
cardiac MRI studies used in epidemiology studies, it gives a
flavor of the type of work done recently. It is clear that cardiac
MRI encodes a lot of information of importance to cardiovas-
cular diseases. One should also recognize that gadolinium
contrast-enhanced MRI adds significantly to the prediction
of coronary heart disease assessment and prognostication over
a non-contrast MRI.
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